| 國立成功大學 |
2023 |
Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment
|
Chang, P.-Y.;Lee, R.-C.;Liang, P.-C.;Liu, Y.-S.;Chuang, V.P.;Wu, D.-K.;Cheng, Y.-F.;Huang, J.-I.;Tseng, H.-S.;Hung, C.-F.;Wu, R.-H.;Chern, M.-C.;Cheng, H.-M.;Wu, C.-H.;Cheng, S.-M.;Chiang, Chiang C.-L.;Liang, H.-L. |
| 臺大學術典藏 |
2022-09-15T03:00:15Z |
Quantification of Abdominal Muscle Mass and Diagnosis of Sarcopenia with Cross-Sectional Imaging in Patients with Polycystic Kidney Disease: Correlation with Total Kidney Volume
|
Wu C.-H.; Lai T.-S.; YUNG-MING CHEN; Chen C.-M.; Yang S.-C.; Liang P.-C. |
| 臺大學術典藏 |
2022-09-14T01:29:27Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: A preliminary result
|
Liang P.-C.; Ch'ang H.-J.; CHIUN HSU; Tseng S.S.; Shih T.T.F.; Wu Liu T. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; CHIUN HSU; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2022-08-19T00:20:51Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Liu K.-L.; Liang P.-C.; Shih T.T.-F.; Chen C.-H.; CHIUN HSU; Wu C.-H.; Shih I.-L.; Chen B.-B. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:41Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Ni Y.-H.; Lin C.-L.; Hsu Y.-C.; Hsu C.-W.; Wu C.-Y.; Wu J.-C.; Cheng J.C.-H.; Leung S.W.; Chen S.-W.; Hsu H.-C.; Hong J.-H.; Wang P.-M.; Wang P.-M.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; CHIUN HSU; Chao Y.; Chen L.-T.; Lee P.-H.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Hung C.-F.; Huang S.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N. |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Lin Z.-Z.; Hsu C.-H.; Liang P.-C.; Chen B.-B.; Shao Y.-Y.; CHIUN HSU; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Lin Z.-Z.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Shao Y.-Y.; Hsu C.-H.; CHIUN HSU; Liang P.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:25Z |
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
|
Liang P.-C.; Liu T.-H.; Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chen B.-B.; Shih T.T.-F.; Shen Y.-C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:14Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Shao Y.-Y.; ZHONG-ZHE LIN; Liang P.-C.; Tien Y.-W.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:06Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN |
| 臺大學術典藏 |
2022-06-10T06:10:53Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; ZHONG-ZHE LIN; Shao Y.-Y.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-06-10T06:10:53Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-06-10T06:10:52Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; Liu T.-H.; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; ZHONG-ZHE LIN |
| 臺大學術典藏 |
2022-05-12T01:36:49Z |
Computed tomography-based sarcopenia in patients receiving peritoneal dialysis: Correlation with lean soft tissue and survival
|
Wu C.H.; CHIA-TER CHAO; Liang P.C.; Shih T.T.F.; Huang J.W. |
| 臺大學術典藏 |
2022-04-07T01:43:07Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; TSUNG-HAO LIU; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-03-08T03:44:04Z |
Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan
|
Chang M.-C.; Wu C.-H.; SHIH-HUNG YANG; Liang P.-C.; Chen B.-B.; Jan I.-S.; Chang Y.-T.; Jeng Y.-M. |
| 臺大學術典藏 |
2022-03-04T06:55:01Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
SIH-HAN LIAO; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:41Z |
Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma.
|
Liang J.D.; Yang P.M.; Huang G.T.; Lee H.S.; CHIEN-HUNG CHEN; Liang P.C.; Sheu J.C.; Chen D.S. |
| 臺大學術典藏 |
2022-02-23T02:12:28Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:27Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
